166 related articles for article (PubMed ID: 21225315)
1. Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design.
Tevaarwerk A; Wilding G; Eickhoff J; Chappell R; Sidor C; Arnott J; Bailey H; Schelman W; Liu G
Invest New Drugs; 2012 Jun; 30(3):1039-45. PubMed ID: 21225315
[TBL] [Abstract][Full Text] [Related]
2. A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
North B; Kocher HM; Sasieni P
BMC Cancer; 2019 Jun; 19(1):632. PubMed ID: 31242873
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Carducci MA; Musib L; Kies MS; Pili R; Truong M; Brahmer JR; Cole P; Sullivan R; Riddle J; Schmidt J; Enas N; Sinha V; Thornton DE; Herbst RS
J Clin Oncol; 2006 Sep; 24(25):4092-9. PubMed ID: 16943527
[TBL] [Abstract][Full Text] [Related]
4. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.
Esaki T; Hirai F; Makiyama A; Seto T; Bando H; Naito Y; Yoh K; Ishihara K; Kakizume T; Natsume K; Myers A; Doi T
Cancer Sci; 2019 Apr; 110(4):1340-1351. PubMed ID: 30724423
[TBL] [Abstract][Full Text] [Related]
8. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study.
Chao J; Synold TW; Morgan RJ; Kunos C; Longmate J; Lenz HJ; Lim D; Shibata S; Chung V; Stoller RG; Belani CP; Gandara DR; McNamara M; Gitlitz BJ; Lau DH; Ramalingam SS; Davies A; Espinoza-Delgado I; Newman EM; Yen Y
Cancer Chemother Pharmacol; 2012 Mar; 69(3):835-43. PubMed ID: 22105720
[TBL] [Abstract][Full Text] [Related]
9. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
10. A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.
Spreafico A; Delord JP; De Mattos-Arruda L; Berge Y; Rodon J; Cottura E; Bedard PL; Akimov M; Lu H; Pain S; Kaag A; Siu LL; Cortes J
Br J Cancer; 2015 Feb; 112(4):650-9. PubMed ID: 25625276
[TBL] [Abstract][Full Text] [Related]
11. A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors.
Lemech C; Woodward N; Chan N; Mortimer J; Naumovski L; Nuthalapati S; Tong B; Jiang F; Ansell P; Ratajczak CK; Sachdev J
Invest New Drugs; 2020 Dec; 38(6):1815-1825. PubMed ID: 32524319
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors.
Demetri GD; Lo Russo P; MacPherson IR; Wang D; Morgan JA; Brunton VG; Paliwal P; Agrawal S; Voi M; Evans TR
Clin Cancer Res; 2009 Oct; 15(19):6232-40. PubMed ID: 19789325
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
[TBL] [Abstract][Full Text] [Related]
14. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1-d2-d3) in patients with refractory solid tumors.
Campone M; Isambert N; Bourbouloux E; Maury S; Monin-Baroille P; Berille J; Fumoleau P
Cancer Chemother Pharmacol; 2007 Apr; 59(5):689-95. PubMed ID: 17031647
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors.
Weiss GJ; Jameson G; Von Hoff DD; Valsasina B; Davite C; Di Giulio C; Fiorentini F; Alzani R; Carpinelli P; Di Sanzo A; Galvani A; Isacchi A; Ramanathan RK
Invest New Drugs; 2018 Feb; 36(1):85-95. PubMed ID: 28726132
[TBL] [Abstract][Full Text] [Related]
16. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of two dosing schedules of oral BI 847325 in patients with advanced solid tumors.
Schöffski P; Aftimos P; Dumez H; Deleporte A; De Block K; Costermans J; Billiet M; Meeus MA; Lee C; Schnell D; Goeldner RG; Awada A
Cancer Chemother Pharmacol; 2016 Jan; 77(1):99-108. PubMed ID: 26650227
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors.
Tolcher AW; Bendell JC; Papadopoulos KP; Burris HA; Patnaik A; Fairbrother WJ; Wong H; Budha N; Darbonne WC; Peale F; Mamounas M; Royer-Joo S; Yu R; Portera CC; Infante JR
Clin Cancer Res; 2016 Sep; 22(18):4567-73. PubMed ID: 27076626
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
[TBL] [Abstract][Full Text] [Related]
20. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Sweeney CJ; Chiorean EG; Verschraegen CF; Lee FC; Jones S; Royce M; Tye L; Liau KF; Bello A; Chao R; Burris HA
J Clin Oncol; 2010 Oct; 28(29):4513-20. PubMed ID: 20837944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]